AnaptysBio (ANAB) Given a $127.00 Price Target by Stifel Nicolaus Analysts

Stifel Nicolaus set a $127.00 target price on AnaptysBio (NASDAQ:ANAB) in a report published on Friday, September 14th, The Fly reports. The firm currently has a buy rating on the biotechnology company’s stock.

Other analysts also recently issued reports about the company. ValuEngine upgraded AnaptysBio from a hold rating to a buy rating in a research report on Friday, June 1st. Jefferies Financial Group restated a buy rating and issued a $121.00 price objective on shares of AnaptysBio in a research report on Tuesday, August 7th. Zacks Investment Research upgraded AnaptysBio from a hold rating to a buy rating and set a $93.00 price objective on the stock in a research report on Monday, August 13th. Cantor Fitzgerald started coverage on AnaptysBio in a research report on Tuesday, September 4th. They issued a buy rating and a $124.00 price objective on the stock. Finally, JMP Securities reduced their price objective on AnaptysBio from $180.00 to $153.00 and set a buy rating on the stock in a research report on Wednesday, August 15th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock has an average rating of Buy and an average price target of $129.30.

ANAB traded down $2.49 during trading on Friday, reaching $90.44. 299,600 shares of the stock were exchanged, compared to its average volume of 372,666. The company has a debt-to-equity ratio of 0.01, a quick ratio of 16.19 and a current ratio of 16.19. The company has a market cap of $2.40 billion, a price-to-earnings ratio of -60.41 and a beta of 2.77. AnaptysBio has a 1 year low of $34.56 and a 1 year high of $134.00.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.57) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.70) by $0.13. On average, analysts predict that AnaptysBio will post -2.72 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the stock. United Services Automobile Association increased its stake in AnaptysBio by 27.9% in the second quarter. United Services Automobile Association now owns 3,138 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 685 shares during the last quarter. State of Wisconsin Investment Board increased its stake in AnaptysBio by 3.8% during the second quarter. State of Wisconsin Investment Board now owns 18,900 shares of the biotechnology company’s stock worth $1,343,000 after acquiring an additional 700 shares during the last quarter. Teacher Retirement System of Texas increased its stake in AnaptysBio by 28.7% during the second quarter. Teacher Retirement System of Texas now owns 3,335 shares of the biotechnology company’s stock worth $237,000 after acquiring an additional 743 shares during the last quarter. Partner Investment Management L.P. increased its stake in AnaptysBio by 82.8% during the second quarter. Partner Investment Management L.P. now owns 1,709 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 774 shares during the last quarter. Finally, Great West Life Assurance Co. Can increased its stake in AnaptysBio by 65.9% during the second quarter. Great West Life Assurance Co. Can now owns 2,057 shares of the biotechnology company’s stock worth $146,000 after acquiring an additional 817 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.

See Also: What are earnings reports?

The Fly

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply